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Summary
Background Through the Global Burden of Diseases, Injuries, and Risk Factors (GBD) studies, headache has emerged 
as a major global public health concern. We aimed to use data from the GBD 2016 study to provide new estimates for 
prevalence and years of life lived with disability (YLDs) for migraine and tension-type headache and to present the 
methods and results in an accessible way for clinicians and researchers of headache disorders.
Methods Data were derived from population-based cross-sectional surveys on migraine and tension-type headache. 
Prevalence for each sex and 5-year age group interval (ie, age 5 years to ≥95 years) at different time points from 
1990 and 2016 in all countries and GBD regions were estimated using a Bayesian meta-regression model. Disease 
burden measured in YLDs was calculated from prevalence and average time spent with headache multiplied by 
disability weights (a measure of the relative severity of the disabling consequence of a disease). The burden 
stemming from medication overuse headache, which was included in earlier iterations of GBD as a separate 
cause, was subsumed as a sequela of either migraine or tension-type headache. Because no deaths were assigned 
to headaches as the underlying cause, YLDs equate to disability-adjusted life-years (DALYs). We also analysed 
results on the basis of the Socio-demographic Index (SDI), a compound measure of income per capita, education, 
and fertility.
Findings Almost three billion individuals were estimated to have a migraine or tension-type headache in 2016: 
1·89 billion (95% uncertainty interval [UI] 1·71–2·10) with tension-type headache and 1·04 billion (95% UI 1·00–1·09) 
with migraine. However, because migraine had a much higher disability weight than tension-type headache, migraine 
caused 45·1 million (95% UI 29·0–62·8) and tension-type headache only 7·2 million (95% UI 4·6–10·5) YLDs 
globally in 2016. The headaches were most burdensome in women between ages 15 and 49 years, with migraine 
causing 20·3 million (95% UI 12·9–28·5) and tension-type headache 2·9 million (95% UI 1·8–4·2) YLDs in 2016, 
which was 11·2% of all YLDs in this age group and sex. Age-standardised DALYs for each headache type showed a 
small increase as SDI increased.
Interpretation Although current estimates are based on limited data, our study shows that headache disorders, and 
migraine in particular, are important causes of disability worldwide, and deserve greater attention in health policy 
debates and research resource allocation. Future iterations of this study, based on sources from additional countries 
and with less methodological heterogeneity, should help to provide stronger evidence of the need for action.
Funding Bill & Melinda Gates Foundation.
Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
license.
Introduction
Migraine and other headache disorders are among the 
most prevalent disorders worldwide,1 but recognition of 
their importance for public health has come only since 
2000. This delay has occurred in part because headache 
is not fatal and does not result in permanent or objective 
disability, and in part because headaches are 
experienced by most people from time to time, which 
has hindered the realisation that headache disorders 
are debilitating for a relatively large minority of the 
people who are affected.
The Global Burden of Diseases, Injuries, and Risk 
Factors (GBD) studies have as one of their main aims 
the evaluation not only of mortality but also of non-fatal 
health outcomes. GBD offers a method of quantifying 
health loss in time units, enabling comparisons over 
time and across conditions, cultures, and countries, 
and, from 2016, at subnational levels in some countries. 
GBD has become an important tool for priority setting 
and planning of health services by international health 
organisations and governments.
Migraine was not included in GBD 1990, but was added 
in GBD 2000. In GBD 2010, tension-type headache was 
added and in GBD 2013, medication overuse headache 
was included. In GBD 2000, migraine was ranked as the 
19th cause of disability globally.2 For the GBD 2000 study, 
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data were absent for more than half of the world’s 
population. When new data came from big countries like 
Russia, China, India, and some parts of Africa, and with 
tension-type headache and medication overuse headache 
also taken into account, headache disorders were 
collectively the third cause of disability in people under 
50 years of age in GBD 2015.3 Since GBD 2010, prevalence 
and burden of disability have been re-estimated for the 
full time period from 1990 until the most recent year for 
which data are available, each time incorporating new 
data sources and any updates to methods.
Given the importance of headache disorders for 
global public health, which has become evident through 
GBD, we wanted to inform an audience of headache 
specialists about these studies. The aims of the present 
Article are to provide an overview of the GBD methods 
as applied to headache, to present detailed results of the 
update for 1990–2016 on headache burden in different 
world regions and with time trends, and to discuss the 
implications of these results both for future iterations 
of GBD and for health policies around the world.
Methods
Overview
The main elements of the GBD methods, both general 
and pertaining to migraine and tension-type headache, 
are described in the appendix. In the main text of this 
Article, we concentrate on methods pertaining to 
estimation of the burden of migraine and tension-type 
headache. A flowchart of the different steps in these 
methods is shown in the appendix.
In the GBD cause hierarchy, migraine and tension-
type headache are individual disorders on Level 3, 
under neurological disorders (Level 2) and non-
communicable diseases (Level 1). No further 
subdivision exists for headaches, so each reappears at 
Level 4. In GBD 2013 and GBD 2015, medication 
overuse headache was treated as a separate disorder, 
but in GBD 2016 it was considered a sequela of either 
migraine or tension-type headache. The burden of 
medication overuse headache was therefore added to 
the burdens estimated for these headache types 
according to a meta-analysis of three studies reporting 
the proportions of medication overuse headache 
resulting from migraine (73·4%, 95% uncertainty 
interval [UI] 63·9–82·0) or tension-type headache 
(26·6%, 18·0–36·1).4–6
In GBD, disease burden is estimated in disability-
adjusted life-years (DALYs), which are the sum of years 
of life lost (YLLs) to premature mortality and years of 
life lived with disability (YLDs). Because GBD does not 
estimate any deaths from headache disorders as the 
underlying cause, DALYs for headaches are equivalent 
to YLDs. YLDs for each headache disorder are calculated 
from its prevalence and the mean time patients spend 
with that type of headache multiplied by the associated 
disability weight. The determination of headache 
disability weights through population and internet 
surveys was on the basis of lay descriptions (appendix).7,8 
The disability weight for migraine was 0·434, meaning 
that during an attack the affected person experiences 
health loss of 43·4% compared with a person in full 
Research in context
Evidence before this study
Since 2000, the Global Burden of Diseases, Injuries, and Risk 
Factors (GBD) studies have produced estimates of prevalence 
and burden of migraine. Since GBD 2010, tension-type 
headache and medication overuse headache have been added 
and estimates have been made by country spanning the 
period from 1990 to the most recent year for which data are 
available. Headache disorders, and in particular, migraine, 
have been found to be highly prevalent and a cause of large 
burden. To date, no research article has focused on the 
detailed methods and results of headache estimates from 
GBD. With the present study, we updated a previous 
systematic review covering 1980–2001 by doing a review that 
searched PubMed for articles using the terms “migraine”, 
“tension”, “headache”, “medication”, and “epidemiology” 
from Jan 1, 2001, until Dec 31, 2015. There were no language 
restrictions.
Added value of this study
In 2016, of all GBD causes of disease, tension-type headache 
was the third most prevalent, and migraine the sixth. In terms 
of years of life lived with disability, migraine ranked second 
globally, and was among the ten most disabling disorders in 
each of the 21 GBD regions. It was particularly burdensome 
among young and middle-aged women. Unlike many other 
diseases and injuries quantified in GBD studies, headache 
showed no clear relation to sociodemographic development, as 
measured by the Socio-demographic Index. No risk factors have 
yet been established in the GBD studies for headache disorders, 
and headache epidemiological studies are absent in many 
countries and regions.
Implications of all the available evidence
Through the GBD studies, headache disorders, and in particular, 
migraine, have been shown to be among the most disabling 
disorders worldwide. Many fatal and disabling disorders 
decrease with socioeconomic development, but this does not 
seem to be true for migraine and tension-type headache. 
Hence, their relative importance is likely to increase in the 
future. More high-quality headache epidemiological studies 
and studies aiming to identify modifiable risk factors should be 
done. Effective strategies to modify the course of headaches 
and alleviate pain exist, but many people affected by headache 
are not benefiting from this knowledge.
See Online for appendix
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Migraine Tension-type headache
Prevalence YLDs Prevalence YLDs




















Global 1 044 771 478 
(999 534 692 to 
1 087 968 951)
–1·8% 
(–2·0 to –1·5)
45 121 909 




1 890 670 389 
(1 707 786 493 to 
2 097 761 629)
–7·3% 
(–7·8 to –6·7)
7 195 122 




High SDI 167 752 331 




7 183 304 




245 115 740 




1 055 366 




High-middle SDI 172 643 687 




7 760 262 




307 673 576 




1 327 611 




Middle SDI 294 085 908 




12 911 188 




569 499 609 




2 160 117 




Low-middle SDI 329 933 660 




13 869 352 




596 330 852 




2 096 630 




Low SDI 84 126 809 




3 546 725 




175 779 968 











53 344 669 




2 276 046 




74 430 873 









Canada 6 301 113 





(168 731 to 371 278)
–6·8% 
(–9·8 to –3·5)
8 696 062 
























USA 47 016 985 




2 010 075 




65 697 424 









Australasia 5 334 994 









8 124 243 





(18 804 to 43 770)
–0·7% 
(–4·6 to 3·9)
Australia 4 543 179 





(119 136 to 263 360)
–0·6% 
(–3·7 to 2·8)
6 841 911 




(15 828 to 36 960)
–0·7% 
(–5·2 to 4·7)
New Zealand 791 815 





(20 979 to 46 303)
0·0% 
(–3·2 to 3·5)
1 282 332 










27 032 727 




1 137 019 




49 382 811 









Brunei 67 038 















Japan 17 763 393 









33 825 326 









Singapore 577 459 
















South Korea 8 624 838 









14 476 250 





(31 775 to 74 160)
0·1% 
(–4·7 to 5·4)
(Table continues on next page)
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Prevalence YLDs Prevalence YLDs




















(Continued from previous page)
Western Europe 80 808 422 




3 447 004 




107 733 424 









Andorra 15 188 















Austria 1 819 880 





(50 017 to 108 066)
–0·3% 
(–3·2 to 2·5)
2 282 375 





(6626 to 15 484)
–0·2% 
(–5·1 to 5·3)
Belgium 2 124 832 





(59 314 to 127 901)
–0·7% 
(–3·9 to 2·8)
2 822 458 





(8423 to 19 937)
–0·4% 
(–5·4 to 5·8)
Cyprus 183 856 
















Denmark 1 026 797 





(28 840 to 62 190)
–0·1% 
(–3·2 to 3·2)
1 409 715 








Finland 1 012 067 





(28 398 to 61 020)
–0·8% 
(–4·1 to 2·6)
1 351 804 







France 11 892 970 





(332 963 to 715 766)
0·7% 
(–2·4 to 4·2)
13 357 050 









Germany 14 730 968 





(401 735 to 869 239)
–0·8% 
(–4·0 to 2·5)
20 673 287 









Greece 2 014 931 





(57 132 to 122 557)
–0·7% 
(–3·6 to 2·4)
2 669 218 





(8196 to 19 424)
0·1% 
(–5·5 to 5·8)
Iceland 61 873 















Ireland 880 498 





(24 481 to 53 165)
–0·1% 
(–3·3 to 3·3)
1 154 239 








Israel 1 457 632 





(40 143 to 87 951)
–0·6% 
(–3·8 to 3·0)
2 010 964 





(5377 to 12 912)
–0·3% 
(–5·2 to 5·1)
Italy 12 977 731 





(343 210 to 753 112)
0·1% 
(–2·8 to 3·3)
16 789 700 





(43 106 to 99 628)
–0·8% 
(–6·0 to 5·0)
Luxembourg 122 651 
















Malta 80 226 















Netherlands 3 489 189 





(90 809 to 199 718)
0·2% 
(–2·8 to 3·2)
4 834 235 





(11 610 to 26 839)
–0·1% 
(–4·7 to 5·1)
Norway 895 018 





(24 456 to 53 206)
0·4% 
(–2·9 to 3·8)
1 340 876 








Portugal 2 051 173 





(57 161 to 124 408)
–0·3% 
(–3·7 to 3·3)
2 783 841 





(8150 to 19 223)
0·2% 
(–4·8 to 5·8)
(Table continues on next page)
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(Continued from previous page)
Spain 9 449 914 





(261 007 to 570 711)
–0·5% 
(–3·5 to 2·8)
11 981 430 





(35 172 to 83 084)
0·6% 
(–4·7 to 6·5)
Sweden 1 487 390 





(42 366 to 90 761)
–1·1% 
(–3·5 to 1·6)
2 422 653 




(6700 to 15 201)
0·2% 
(–3·4 to 4·2)
Switzerland 1 610 830 





(45 338 to 98 043)
–0·4% 
(–3·5 to 2·9)
1 832 194 





(6146 to 14 649)
0·5% 
(–4·4 to 6·0)
UK 11 340 953 





(322 502 to 691 283)
–0·4% 
(–1·0 to 0·2)
17 297 990 











10 694 738 









17 026 105 





(39 481 to 90 851)
0·8% 
(–2·5 to 4·7)
Argentina 7 110 301 









11 317 606 





(26 069 to 60 175)
0·4% 
(–4·4 to 5·5)
Chile 3 026 313 





(80 166 to 177 701)
–0·9% 
(–4·2 to 2·5)
4 807 703 





(11 347 to 26 106)
1·7% 
(–3·2 to 7·0)
Uruguay 557 656 
















Eastern Europe 36 522 399 




1 666 165 




60 047 323 









Belarus 1 699 640 





(50 929 to 109 943)
–0·1% 
(–3·7 to 3·5)
2 902 221 





(8699 to 21 853)
0·6% 
(–5·2 to 6·5)
Estonia 225 237 
















Latvia 342 799 
















Lithuania 510 354 
















Moldova 745 403 





(22 171 to 47 267)
–0·4% 
(–3·7 to 3·1)
1 337 141 








Russia 24 812 212 




1 124 516 




39 795 927 









Ukraine 8 186 753 





(245 301 to 529 894)
–0·1% 
(–3·9 to 4·0)
14 142 775 









Central Europe 18 993 317 









29 140 306 









Albania 470 177 
















(Table continues on next page)
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(19 404 to 41 666)
–0·9% 
(–4·1 to 2·5)
1 013 644 







Bulgaria 1 181 688 





(36 529 to 78 549)
–0·7% 
(–4·2 to 2·8)
1 815 845 





(6391 to 14 963)
–0·7% 
(–5·8 to 4·8)
Croatia 679 780 





(20 986 to 44 579)
–0·4% 
(–3·5 to 2·8)
1 033 878 







Czech Republic 1 722 598 





(52 955 to 114 677)
–0·9% 
(–4·4 to 2·5)
2 614 501 





(9256 to 21 746)
–1·1% 
(–5·7 to 4·2)
Hungary 1 629 447 





(50 433 to 107 353)
–0·3% 
(–3·9 to 3·2)
2 492 086 





(8661 to 20 435)
–0·2% 
(–5·2 to 5·3)
Macedonia 345 962 
















Montenegro 101 028 















Poland 6 377 038 





(195 947 to 422 082)
–0·3% 
(–3·4 to 3·1)
9 750 850 





(33 946 to 79 509)
–0·1% 
(–5·2 to 5·7)
Romania 3 174 876 





(97 035 to 207 629)
0·0% 
(–3·2 to 3·3)
4 843 083 





(16 888 to 39 894)
–0·2% 
(–5·0 to 5·6)
Serbia 1 430 906 





(43 486 to 92 732)
–0·5% 
(–3·8 to 2·9)
2 246 471 





(7429 to 17 420)
–0·8% 
(–5·5 to 4·5)
Slovakia 908 113 





(27 978 to 60 511)
–0·6% 
(–3·9 to 3·0)
1 380 345 




(4827 to 11 471)
–0·6% 
(–5·4 to 4·6)
Slovenia 332 244 
















Central Asia 13 736 082 









24 381 639 









Armenia 504 582 
















Azerbaijan 1 600 921 





(44 683 to 96 691)
–1·0% 
(–4·2 to 2·6)
2 774 204 





(6885 to 15 956)
–0·8% 
(–5·3 to 3·8)
Georgia 647 211 





(18 220 to 39 473)
–0·5% 
(–3·7 to 3·0)
1 123 285 








Kazakhstan 2 766 716 





(75 684 to 165 930)
–0·2% 
(–3·5 to 3·3)
4 822 123 





(11 814 to 27 281)
0·0% 
(–4·7 to 5·3)
Kyrgyzstan 901 584 





(24 434 to 54 387)
–0·1% 
(–3·4 to 3·4)
1 645 510 








(Table continues on next page)
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(Continued from previous page)
Mongolia 472 326 
















Tajikistan 1 262 201 





(34 428 to 75 752)
–0·4% 
(–3·6 to 3·1)
2 359 192 





(5188 to 12 137)
–0·2% 
(–5·1 to 5·0)
Turkmenistan 855 817 





(23 531 to 51 851)
–0·4% 
(–3·6 to 3·1)
1 502 813 








Uzbekistan 4 724 725 





(129 874 to 280 721)
–0·1% 
(–3·6 to 3·4)
8 436 261 










34 762 545 




1 660 602 




72 991 274 









Colombia 7 037 533 





(217 516 to 466 079)
0·1% 
(–3·1 to 3·5)
13 988 578 





(41 256 to 95 361)
–1·1% 
(–6·2 to 4·5)
Costa Rica 690 578 





(21 674 to 46 323)
0·2% 
(–3·2 to 3·6)
1 386 207 







El Salvador 861 889 





(26 577 to 57 355)
1·5% 
(–1·9 to 4·9)
1 782 909 





(4950 to 11 433)
–0·6% 
(–5·7 to 5·3)
Guatemala 2 118 201 





(63 165 to 136 729)
1·1% 
(–2·4 to 4·6)
4 583 592 





(11 815 to 27 162)
–0·6% 
(–6·0 to 5·2)
Honduras 1 099 359 





(32 866 to 72 093)
0·2% 
(–3·3 to 3·9)
2 345 459 





(6194 to 14 381)
–1·3% 
(–6·1 to 4·1)
Mexico 17 294 301 









37 432 220 









Nicaragua 843 871 





(25 685 to 55 728)
0·2% 
(–3·2 to 3·9)
1 768 388 





(4844 to 11 172)
–1·5% 
(–6·6 to 4·4)
Panama 540 954 





(16 679 to 36 516)
0·2% 
(–3·0 to 3·9)
1 083 812 







Venezuela 4 275 858 





(132 318 to 283 996)
0·5% 
(–2·8 to 4·1)
8 620 107 










7 900 228 









15 134 012 









Bolivia 1 384 973 





(41 372 to 89 926)
0·0% 
(–3·6 to 3·8)
2 772 129 





(7 412 to 17 352)
–1·1% 
(–6·2 to 4·7)
Ecuador 2 045 883 





(62 821 to 137 300)
0·0% 
(–3·4 to 3·1)
4 184 493 





(11 909 to 27 908)
–1·1% 
(–5·9 to 4·4)
Peru 4 469 372 





(133 541 to 292 162)
–0·6% 
(–3·7 to 2·9)
8 177 390 




(23 233 to 55 383)
–0·6% 
(–5·6 to 4·7)
(Table continues on next page)
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(Continued from previous page)
Caribbean 6 508 546 









13 706 101 





(36 307 to 85 384)
–1·8% 
(–4·5 to 0·9)
Antigua and Barbuda 13 734 















The Bahamas 58 695 















Barbados 41 798 















Belize 50 816 















Bermuda 10 187 















Cuba 1 708 831 





(53 101 to 114 169)
–0·3% 
(–3·6 to 2·9)
3 454 818 





(10 081 to 23 690)
–1·7% 
(–6·2 to 3·4)
Dominica 10 714 















Dominican Republic 1 469 656 





(43 787 to 94 794)
0·1% 
(–3·1 to 3·5)
3 092 021 





(8145 to 19 063)
–1·4% 
(–6·3 to 4·0)
Grenada 15 150 















Guyana 108 275 
















Haiti 1 491 507 





(42 627 to 92 230)
–0·4% 
(–3·9 to 3·1)
3 393 664 





(7695 to 17 990)
–1·8% 
(–6·4 to 3·4)
Jamaica 406 638 
















Puerto Rico 538 458 





(16 718 to 36 404)
–0·9% 
(–4·3 to 2·6)
1 063 365 







Saint Lucia 27 432 















Saint Vincent and the 
Grenadines
15 937 















Suriname 78 191 















Trinidad and Tobago 204 165 
















Virgin Islands 14 900 

















34 400 664 




1 509 125 




79 012 630 









Brazil 33 392 533 




1 465 378 




76 805 591 









(Table continues on next page)
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(Continued from previous page)
Paraguay 1 008 131 





(27 869 to 61 297)
–1·3% 
(–4·7 to 2·1)
2 207 039 





(4730 to 11 145)
–3·0% 
(–7·7 to 2·6)
East Asia 138 171 702 




6 165 860 




269 879 994 




1 058 408 




China 132 930 661 




5 938 315 




260 794 517 




1 022 673 




North Korea 2 593 897 





(71 390 to 159 152)
–1·8% 
(–5·6 to 2·0)
4 963 157 





(11 376 to 27 487)
–1·3% 
(–6·9 to 4·0)
Taiwan (province of 
China)
2 647 143 





(73 874 to 160 100)
1·2% 
(–2·7 to 5·5)
4 122 320 





(11 118 to 25 979)
2·0% 
(–3·5 to 8·3)
Southeast Asia 84 397 472 




3 466 178 




176 724 151 









Cambodia 1 972 188 





(50 572 to 113 503)
–0·5% 
(–4·4 to 3·4)
4 282 356 





(7381 to 18 296)
–1·3% 
(–6·1 to 4·1)
Indonesia 33 130 967 




1 359 211 




71 377 953 









Laos 819 097 





(20 889 to 47 575)
–0·3% 
(–4·3 to 3·4)
1 803 437 








Malaysia 3 911 967 





(102 972 to 228 271)
–0·6% 
(–4·2 to 3·3)
7 989 485 





(15 173 to 36 772)
–1·6% 
(–6·5 to 4·3)
Maldives 47 268 















Mauritius 171 325 
















Myanmar 7 065 448 





(184 100 to 409 943)
–0·5% 
(–4·2 to 3·2)
14 831 091 





(26 887 to 65 583)
–2·0% 
(–7·1 to 4·2)
Philippines 12 301 469 





(319 478 to 716 513)
–0·3% 
(–3·9 to 3·4)
25 812 371 









Sri Lanka 2 685 239 





(70 439 to 157 347)
0·8% 
(–3·1 to 4·9)
5 407 181 





(10 412 to 25 103)
–0·2% 
(–5·3 to 5·3)
Seychelles 12 522 















Thailand 9 517 252 





(252 248 to 555 245)
–1·2% 
(–5·1 to 2·4)
18 391 437 





(36 905 to 87 121)
–1·5% 
(–6·2 to 4·2)
Timor-Leste 124 351 
















Vietnam 12 526 388 





(328 938 to 728 504)
–1·2% 
(–4·9 to 2·5)
25 861 953 









(Table continues on next page)
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Oceania 1 160 780 





(29 927 to 66 877)
–0·7% 
(–3·6 to 2·0)
2 498 945 





(4600 to 11 094)
–0·9% 
(–4·4 to 2·9)
















Federated States of 
Micronesia
10 657 















Fiji 97 017 















Guam 18 623 















Kiribati 12 021 

















































Papua New Guinea 800 421 





(20 454 to 45 996)
–0·9% 
(–4·7 to 2·9)
1 757 374 








Samoa 18 992 















Solomon Islands 59 294 















Tonga 10 616 















Vanuatu 27 789 















North Africa and 
Middle East
93 437 442 




4 289 081 




175 091 388 









Afghanistan 4 841 208 





(134 134 to 294 141)
0·5% 
(–3·4 to 4·4)
9 939 058 





(22 613 to 53 732)
1·5% 
(–3·1 to 6·5)
Algeria 6 651 343 





(199 203 to 431 278)
1·2% 
(–2·2 to 4·3)
12 127 472 





(35 743 to 84 961)
2·9% 
(–2·6 to 9·2)
Bahrain 240 046 
















Egypt 14 623 084 





(433 516 to 936 625)
0·9% 
(–2·5 to 4·9)
26 934 828 









Iran 13 616 955 





(425 780 to 905 798)
2·3% 
(–1·0 to 5·7)
26 496 199 









Iraq 5 534 181 





(157 277 to 342 808)
0·6% 
(–2·9 to 4·3)
10 732 501 





(27 365 to 64 414)
1·7% 
(–3·1 to 7·1)
Jordan 1 203 358 





(35 403 to 77 551)
1·9% 
(–1·7 to 5·5)
2 196 597 





(6276 to 14 876)
3·7% 
(–1·6 to 9·6)
(Table continues on next page)
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Kuwait 712 246 





(21 841 to 48 110)
0·6% 
(–3·1 to 4·3)
1 250 436 








Lebanon 1 017 537 





(30 941 to 66 597)
0·5% 
(–2·9 to 3·9)
1 795 208 





(5586 to 13 274)
2·8% 
(–2·3 to 8·7)
Libya 1 054 747 





(32 133 to 69 680)
3·3% 
(–0·3 to 7·3)
1 837 414 





(5661 to 13 629)
4·4% 
(–0·9 to 10·8)
Morocco 5 883 012 





(174 130 to 382 333)
1·3% 
(–2·3 to 5·1)
10 851 241 





(31 448 to 73 822)
3·3% 
(–2·3 to 9·4)
Oman 773 924 





(23 376 to 50 763)
–3·5% 
(–7·4 to 0·9)
1 476 286 





(4261 to 10 363)
0·9% 
(–6·7 to 9·2)
Palestine 714 895 





(20 345 to 44 967)
0·2% 
(–3·1 to 3·5)
1 399 904 







Qatar 395 766 
















Saudi Arabia 5 797 325 





(172 575 to 373 293)
2·8% 
(0·8 to 4·9)
8 683 665 





(28 544 to 65 886)
5·3% 
(–0·3 to 10·5)
Sudan 6 119 599 





(176 305 to 381 268)
1·2% 
(–2·2 to 4·7)
11 733 161 





(30 469 to 71 699)
3·0% 
(–2·1 to 9·0)
Syria 2 864 674 





(84 689 to 183 571)
1·4% 
(–2·0 to 5·3)
5 310 861 





(14 638 to 34 911)
3·5% 
(–2·3 to 9·9)
Tunisia 1 898 520 





(58 559 to 124 945)
1·8% 
(–1·5 to 5·4)
3 545 921 





(10 721 to 25 799)
3·3% 
(–2·3 to 9·4)
Turkey 13 712 859 





(397 735 to 854 395)
0·9% 
(–2·3 to 4·3)
26 323 266 









United Arab Emirates 1 566 357 





(49 496 to 107 622)
–1·2% 
(–4·8 to 2·8)
3 050 507 





(9215 to 23 288)
0·5% 
(–5·2 to 6·8)
Yemen 4 113 092 





(115 752 to 254 144)
0·2% 
(–3·2 to 3·7)
8 070 505 





(19 858 to 47 513)
2·5% 
(–2·9 to 9·2)
South Asia 297 880 096 




12 432 812 




499 729 138 




1 801 808 




Bangladesh 29 833 591 




1 251 149 




49 777 226 









Bhutan 143 348 
















India 231 458 617 




9 642 457 




384 460 770 




1 392 107 




(Table continues on next page)
Articles
www.thelancet.com/neurology   Vol 17   November 2018 965
Migraine Tension-type headache
Prevalence YLDs Prevalence YLDs




















(Continued from previous page)
Nepal 5 671 848 





(148 304 to 328 137)
0·5% 
(–2·4 to 3·5)
8 813 328 





(19 939 to 46 563)
2·8% 
(–2·3 to 8·5)
Pakistan 30 772 692 




1 299 007 




56 439 842 











8 855 681 









18 825 137 





(41 251 to 95 803)
–0·7% 
(–2·8 to 1·6)
Botswana 263 435 
















Lesotho 235 920 
















Namibia 274 485 
















South Africa 6 276 496 





(176 270 to 376 825)
–1·1% 
(–2·5 to 0·5)
13 305 448 





(29 748 to 68 641)
–0·8% 
(–3·1 to 1·7)
Swaziland 140 193 
















Zimbabwe 1 665 152 





(44 789 to 99 425)
–0·1% 
(–3·7 to 3·4)
3 616 284 










43 730 076 




1 812 846 




93 543 672 









Benin 1 272 254 





(33 155 to 74 425)
–0·9% 
(–4·3 to 2·7)
2 743 528 





(5110 to 12 303)
0·2% 
(–4·6 to 5·5)
Burkina Faso 2 043 309 





(53 437 to 119 037)
0·0% 
(–3·8 to 3·9)
4 536 772 





(8149 to 20 294)
1·0% 
(–3·4 to 6·2)
Cameroon 2 654 052 





(69 463 to 155 810)
0·2% 
(–3·5 to 4·0)
5 632 723 





(10 715 to 26 035)
1·4% 
(–3·8 to 6·4)
Cape Verde 67 017 















Chad 1 523 050 





(39 362 to 88 327)
–0·4% 
(–4·2 to 3·5)
3 373 712 





(6049 to 14 901)
0·9% 
(–3·9 to 5·7)
Côte d’Ivoire 2 571 760 





(67 451 to 150 428)
2·0% 
(–1·8 to 5·7)
5 497 208 





(10 415 to 25 119)
2·7% 
(–2·0 to 8·1)
The Gambia 221 140 













(879 to 2 33)
2·8% 
(–2·0 to 8·0)
Ghana 3 249 877 





(87 026 to 192 236)
1·3% 
(–2·4 to 4·9)
6 764 987 





(13 352 to 32 032)
2·3% 
(–2·4 to 7·7)
(Table continues on next page)
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(Continued from previous page)
Guinea 1 450 515 





(38 449 to 85 019)
–0·2% 
(–3·7 to 3·4)
3 176 932 





(5924 to 14 199)
1·0% 
(–3·8 to 6·0)
Guinea-Bissau 216 496 
















Liberia 523 128 





(13 569 to 30 321)
0·1% 
(–3·8 to 3·9)
1 141 762 








Mali 1 915 462 





(50 554 to 111 259)
–0·4% 
(–4·2 to 3·7)
4 270 772 





(7680 to 18 858)
0·8% 
(–3·8 to 5·9)
Mauritania 476 034 
















Niger 2 091 231 





(54 389 to 122 758)
–0·7% 
(–4·3 to 2·9)
4 735 150 





(8498 to 20 664)
0·9% 
(–3·6 to 5·8)
Nigeria 20 102 348 









42 325 359 









São Tomé and 
Príncipe
21 799 















Senegal 1 729 552 





(45 475 to 101 959)
0·9% 
(–3·1 to 4·7)
3 758 765 





(7030 to 16 958)
2·0% 
(–2·4 to 6·9)
Sierra Leone 751 211 





(19 779 to 44 054)
0·1% 
(–3·7 to 3·7)
1 628 771 








Togo 849 307 





(22 304 to 50 067)
0·2% 
(–3·6 to 3·9)
1 822 412 










35 406 307 




1 521 377 




77 059 874 









Burundi 1 058 994 





(29 050 to 64 184)
0·1% 
(–3·4 to 3·9)
2 419 541 




(4781 to 11 540)
–1·4% 
(–6·5 to 4·4)
Comoros 77 572 















Djibouti 94 816 















Eritrea 508 641 





(14 069 to 30 946)
–0·4% 
(–4·3 to 3·5)
1 130 826 








Ethiopia 9 229 249 





(254 815 to 560 661)
1·1% 
(–2·7 to 5·1)
17 741 436 





(41 347 to 97 318)
–3·1% 
(–9·1 to 3·6)
Kenya 4 461 186 





(123 631 to 270 326)
–1·0% 
(–1·9 to 0·0)
10 067 590 





(20 978 to 49 112)
–2·6% 
(–5·4 to 0·5)
Madagascar 2 374 755 





(65 469 to 144 565)
0·6% 
(–3·3 to 4·4)
5 283 896 





(10 894 to 25 710)
–1·0% 
(–6·2 to 5·0)
(Table continues on next page)
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Malawi 1 606 835 





(43 541 to 97 676)
–1·1% 
(–4·9 to 2·8)
3 628 261 





(7305 to 17 329)
–2·5% 
(–7·7 to 3·6)
Mozambique 2 629 177 





(70 810 to 157 682)
–1·5% 
(–5·4 to 2·4)
5 946 894 





(11 929 to 27 700)
–2·8% 
(–7·9 to 3·4)
Rwanda 1 172 540 





(31 976 to 70 958)
1·0% 
(–2·9 to 5·6)
2 565 086 





(5236 to 12 658)
–1·8% 
(–7·3 to 4·9)
Somalia 989 744 





(27 076 to 59 527)
0·0% 
(–3·8 to 4·0)
2 277 745 





(4481 to 10 831)
–1·3% 
(–6·1 to 4·2)
South Sudan 1 220 526 





(33 039 to 73 017)
1·2% 
(–2·8 to 5·3)
2 870 947 





(5552 to 13 259)
–0·8% 
(–5·6 to 5·0)
Tanzania 4 763 051 





(131 056 to 289 453)
–0·3% 
(–4·0 to 3·6)
10 878 846 





(22 485 to 53 261)
–0·9% 
(–6·1 to 5·3)
Uganda 3 521 034 





(95 656 to 212 957)
0·2% 
(–4·0 to 4·2)
7 878 653 





(15 778 to 37 521)
–1·9% 
(–7·4 to 4·5)
Zambia 1 674 732 





(44 394 to 98 653)
–1·0% 
(–4·4 to 2·6)
3 943 390 










11 692 589 









26 207 351 









Angola 2 487 245 





(65 982 to 146 917)
–0·2% 
(–3·8 to 3·7)
5 461 252 
















(14 527 to 31 973)
0·4% 
(–3·1 to 4·5)
1 229 346 








Congo (Brazzaville) 478 926 





(13 032 to 28 445)
0·1% 
(–3·5 to 3·9)
1 018 864 









7 907 386 





(208 899 to 463 527)
0·9% 
(–2·6 to 4·8)
17 930 616 





(34 017 to 81 520)
1·1% 
(–3·3 to 6·2)
Equatorial Guinea 89 144 















Gabon 186 172 
















95% uncertainty intervals are in parentheses. YLDs=years of life lived with disability. SDI=Socio-demographic Index.
Table: Prevalent cases and YLDs for migraine and tension-type headache in 2016 and percentage change of age-standardised rates by location
health. The disability weight for medication overuse 
headache was 0·223 and for tension-type headache was 
0·037. After all diseases were estimated separately, an 
adjustment was made to YLDs to account for 
comorbidity by use of simulation methods assuming a 
multiplicative, rather than additive, model. This 
adjustment led to a downward correction for YLDs for 
migraine in women and children by factors ranging 
from 2·1% (at ages 5–9 years) to 20·6% (at ages 
≥95 years), reflecting a strong correlation between 
comorbidity and age. The corresponding figures in 
males were 2·1% and 20·7%, respectively.
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Data sources
For headaches, the data sources were mostly published 
population-based studies of prevalence; however, 
survey data for which we had the individual record data 
were also included. The PubMed search terms are 
shown in the appendix. Reference lists in published 
articles were reviewed and data were solicited from our 
GBD network of more than 2500 collaborators.
Only studies diagnosing the headaches according to 
the International Classification of Headache Disorders 
(ICHD) were considered. This classification was first 
published in 1988, updated in 2004 (ICHD-2),9 and 
updated again in 2018 (ICHD-3).10 In the three ICHD 
versions, no major differences exist with regard to 
diagnostic criteria of migraine, tension-type headache, 
and medication overuse headache. For evaluation of 
headache burden, these diagnoses were selected because 
they are, by far, the most common and of the greatest 
public health importance.11 Cluster headache causes 
severe pain and disability, but with a lifetime prevalence 
of approximately 0·2% the effect on public health is 
much less.1 Diagnosis of the many secondary headaches 
(eg, due to infections or brain tumours) is difficult in 
epidemiological studies, and the burden of these 
headaches should be attributed to the underlying 
disorder.11 An exception is secondary head ache caused by 
medication overuse, which occurs almost exclusively in 
patients with either migraine or tension-type headache.
For GBD 2016, data on migraine were extracted from 
135 studies, covering 16 of the 21 GBD world regions. 
For tension-type headache, data were extracted from 
76 studies covering 16 GBD regions. All data sources 
are available online. For medication overuse headache, 
data were extracted from 37 studies from ten regions 
(for details about the numbers of studies from each 
region see the appendix). In addition, hospital claims 
data from the USA on migraine and tension-type 
headache for 3 years (2000, 2010, and 2012) were 
used.12–14 Sets of claims data were included because, 
owing to their size, they provide more detailed 
information on age patterns and time trends than 
published epidemiological studies, and also provide 
estimates on subnational locations. Because claims 
data might not be nationally representative, do not refer 
to the ICHD criteria, and capture only those individuals 
who are able to seek health care, they are evaluated for 
systematic biases compared with data sources of high 
quality (appendix).
Approximately half of the 135 studies from which data 
were extracted were from three of the 21 GBD regions 
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Figure 1: Age-standardised prevalence of migraine per 100 000 population by location for both sexes, 2016
ATG=Antigua and Barbuda. FSM=Federated States of Micronesia. LCA=Saint Lucia. TLS=Timor-Leste. TTO=Trinidad and Tobago. VCT=Saint Vincent and the Grenadines.
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(western Europe, high-income North America, and 
high-income Asia Pacific), and no data on any of the 
headaches were available from the Caribbean, central 
sub-Saharan Africa, southern sub-Saharan Africa, or 
Oceania (see appendix) regions. In all regions and 
countries, prevalence was estimated with a Bayesian 
meta-regression model (DisMod-MR 2.1), and estimates 
were obtained in this way also for countries and regions 
where no relevant headache studies had been done.
Calculation of proportion of time in the symptomatic 
state
Headache disorders are modelled as chronic episodic 
conditions. The prevalence reflects the individuals in 
the population who have had at least one episode in the 
past 12 months fulfilling ICHD criteria. To calculate the 
average proportion of time with headache (ie, in the 
symptomatic state) necessary for YLD calculation, 
13 population-based studies were identified that had 
data on frequency and duration of migraine attacks 
(appendix). From these studies, we estimated the 
average number of hours migraineurs spend in attacks, 
and expressed this as a proportion of a year, which was 
8·5% (95% UI 5·8–11·2).
For tension-type headache, seven studies on duration 
and frequency of attacks showed that affected people 
spend, on average, 4·7% (95% UI 1·3–8·0) of their time 
with headache. For both migraine and tension-type 
headache, frequency and duration were reported most 
commonly in categories, and the midpoint was 
assumed to represent each category. For medication 
overuse headache, only one study included in GBD 
2016 (from Russia) gave data on time in symptomatic 
state, reporting a mean headache frequency of 23·1 
(SD 6·7) days per month.15 According to the ICHD-3 
definition, medication overuse headache is present on 
more than 15 days per month for more than 3 months.10
Modelling of prevalence
In the mathematical modelling, the mortality due to 
headache was set at zero,16 as was occurrence below age 
5 years.17 In the sources used for this study, prevalence 
rates vary, but the degree to which this reflects real 
variation across borders and time, or methodological 
differences, is mostly not known. Method most 
probably plays a large role because results can be 
substantially influenced by relatively minor differences, 
such as variations in the screening question.18 To adjust 
for differences in methodological quality, all prevalence 
studies included in GBD are scored according to a 
modified version (dichotomised variables) of published 
methodological quality criteria for headache epidemio-
logical studies,11 taking into account the repre sen-
tativeness of the population of interest (representative 
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Figure 2: Age-standardised prevalence of tension-type headache per 100 000 population by location for both sexes, 2016
 ATG=Antigua and Barbuda. FSM=Federated States of Micronesia. LCA=Saint Lucia. TLS=Timor-Leste. TTO=Trinidad and Tobago. VCT=Saint Vincent and the Grenadines.
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of country or community vs selected population), 
quality of sampling (random sample of the population 
of interest vs not random sample), recall period (1-year 
prevalence vs other recall period), participation rate 
(≥70% vs <70%), survey method (face to face with 
headache expert or trained interviewer vs other), 
validation of diagnostic instrument (sensitivity or 
specificity ≥70% vs <70% or no validation), and 
application of ICHD criteria (strict criteria or reasonable 
modification of criteria vs other modification of 
criteria). In DisMod-MR 2.1, these methodological 
variables were evaluated for a systematic difference and 
corrected accordingly (appendix).
Socio-demographic Index (SDI)
We examined the relationships between migraine and 
tension-type headache DALYs and SDI, a composite 
measure of income per capita, education, and fertility.19 
We also present results by groupings of countries into 
quintiles (high SDI, middle-high SDI, middle SDI, 
middle-low SDI, and low SDI) based on their 2016 SDI 
value. Additional details on the SDI methods can be 
found online. 
Role of the funding source
The funder of the study had no role in study design, 
data collection, data analysis, data interpretation or the 
writing of the report. All authors had full access to the 
data in the study and had final responsibility for the 
decision to submit for publication.
Results
In 2016, almost three billion individuals were estimated 
to have a headache disorder: 1·89 billion (95% UI 
1·71–2·10) with tension-type headache and 1·04 billion 
(95% UI 1·00–1·09) with migraine (table). All data on 
age-standardised prevalence and YLDs for all countries 
and regions, for both 1990 and 2016, are publicly 
available in online visualisations and results download 
tools. For tension-type headache, the global age-
standardised prevalence was 26·1% (23·6–29·0) 
overall: 30·8% (28·0–34·0) for women and 21·4% 
(19·2–23·9) for men. All results for both sexes are 
publicly available online. For migraine, global age-
standardised prevalence was 14·4% (13·8–15·0) overall: 
18·9% (18·1–19·7) for women, and 9·8% (9·4–10·2) for 
men. Maps of age-standardised prevalence of migraine 
and tension-type headache in each country are shown 
in figures 1 and 2. In 2016, the age-standardised 
prevalence of migraine was highest in Italy and Nepal, 
and that of tension-type headache was highest in Brazil 
and Afghanistan. The lowest prevalence of both 
disorders was in China.
Migraine was estimated to have caused 45·1 million 
(95% UI 29·0–62·8) YLDs in 2016 (table), an increase 
of 51·2% (49·7–52·8) from the 29·8 million (19·1–41·8) 
YLDs in 1990 (see online results tool). Tension-type 
headache caused 7·2 million (4·6–10·5) YLDs in 2016 
(table), an increase of 53·1% (47·5–58·4) from the 
4·7 million (3·0–7·0) YLDs in 1990 (online results 
tool). Together, in 2016, migraine and tension-type 
headache caused 52·3 million (34·5–72·5) YLDs 
globally, which was 6·5% of all YLDs: 7·7% among 
women and 5·1% among men. The global age-
standardised YLD rates per 100 000 population for 
migraine were 598·7 (95% UI 385·9–833·3). The 
change from the 1990 values was –0·2% (–0·8 to 0·4). 
For tension-type headache, the global age-standardised 
YLD rate per 100 000 population was 95·9 (61·5–140·0), 
a change of –0·2% (–2·5 to 1·9) from 1990 values. The 
age-standardised YLD rates in 2016 of both disorders 
were higher in women (migraine 777·6, 500·4–1083·6; 
tension-type headache 114·6, 73·6–162·4) than in men 





























Figure 3: Global prevalence of (A) migraine and (B) tension-type headache by age and sex, 2016
Prevalence is expressed as the percentage of the population that is affected by the disease. Shaded areas show 
95% uncertainty intervals. Values are plotted at the midpoint of 5-year age categories.
For the online results tool used 
for estimation see 
http://ghdx.healthdata.org/gbd-
results-tool
For the data visualisations of 
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77·4, 49·6–113·2). The percentage of all YLDs due to 
migraine were 5·6% (4·0–7·2) overall: 6·8% (4·9–8·8) 
for women and 4·3% (3·1–5·5) for men. The corres-
ponding values for tension-type headache were 0·9% 
(0·7–1·2) overall: 1·0% (0·7–1·3) for women and 0·8% 
(0·6–1·0) for men.
For both migraine and tension-type headache, a peak 
in prevalence and YLD rate occurred between ages 
35 and 39 years (figures 3 and 4). In both sexes, the 
percentages of all YLDs were highest in the group aged 
15–49 years (migraine 8·2%, tension-type headache 
1·3%), but was also high in children aged 5–14 years 
(migraine 4·5%, tension-type headache 0·6%), in 
individuals aged 50–69 years (migraine 4·2%, tension-
type headache 0·7%), and in the elderly (ie, ≥70 years; 
migraine 1·3%, tension-type headache 0·3%). In 
women between ages 15 and 49 years, migraine caused 
20·3 million (95% UI 12·9–28·5) and tension-type 
headache caused 2·9 million (95% UI 1·8–4·2) YLDs 
in 2016, which together were 11·2% of all YLDs in this 
age and sex group.
The proportions of all DALYs for both sexes were 
1·9% (1·3–2·5) for migraine and 0·3% (0·2–0·4) for 
tension-type headache. The values were 2·7% (1·8–3·6) 
and 0·4% (0·3–0·5) for women, and 1·2% (0·8–1·7) 
and 0·2% (0·3–0·3) for men. Globally, migraine ranked 
12th of all disorders at GBD cause Level 4 in terms of 
DALYs for both sexes in 2016, up from 17th in 1990. In 
2016, migraine ranked fifth for women (up from 13th in 
1990), and 20th for men (up from 28th in 1990).
Migraine was among the top five Level 4 causes of 
age-standardised YLDs in all five SDI quintiles both in 
1990 and 2016. Age-standardised DALYs for each 
headache type showed a small increase as SDI 
increased. The values estimated for the 21 world 
regions between 1990 and 2016 varied little over time, 
but markedly between regions (figure 5). These results 
indicate that the SDI level of the country is not a major 
determinant of the size of the headache burden.
Discussion
Almost three billion people had a migraine and tension-
type headache together in 2016; tension-type headache 
was the third most prevalent disorder (after dental 
caries and latent tuberculosis infection) and migraine 
the sixth most prevalent out of 328 diseases and injuries 
for which GBD 2016 made estimates.20
GBD 2016 shows that headache, and in particular, 
migraine, is one of the main causes of disability 
worldwide, particularly in young adult and middle-aged 
women (figure 3). Globally, migraine and tension-type 
headache together accounted for 6·5% of all YLDs: 
7·7% among women and 5·1% among men. Headache 
is particularly burdensome in people aged 15–49 years, 
being the cause of 9·5% of all YLDs in this group 
(11·2% among women and 7·5% among men) but the 
effect is not negligible in the group aged 5–14 years 
(5·1%), or among the group aged 50–69 years (4·9%), 
and the group aged 70 years or older (1·6%). Together 
the two disorders are the cause of more than 2% of all 
DALYs: almost 3% in women and almost 1·5% in men.
When analysed at cause Level 4, migraine was the 
second cause of disability after low back pain and 
ranked among the top ten causes of YLDs (age-
standardised) in all 195 countries, both in 1990 and in 
2016.20 In 2016, it ranked first in two regions, second in 
nine, third in five, fourth in two, fifth in two, and sixth 
in one region. Globally, tension-type headache ranked 
28th in both 1990 and 2016.
The increase in YLDs between 1990 and 2016 reflects 
population growth and potentially some effect of a 
change in the age composition of many populations 
(ie, fewer children and adolescents and more middle-
aged people). The fact that age-standardised YLD rates 
are unchanged indicates that, overall, the underlying 
causes of headache have remained the same. Any 
improvements in the efficacy of headache treatments 
during this period (which saw the introduction of 
triptans for migraine) have had no detectable effect—
perhaps partly a reflection of how poorly available they 
are worldwide21 and of the scarcity of data on the 
proportion of time patients are symptomatic, which did 
not allow us to find a treatment effect over time and by 
location. In the DALY rankings, headaches are higher 
in 2016 than in 1990, because of an overall decrease in 
YLLs from fatal disorders. In general, DALY rates for 
non-communicable diseases increase rapidly with age;22 
hence, counts of deaths and DALYs from non-commun-
icable diseases will increase in ageing populations. 























Figure 4: Global years of life lived with disability (YLD) rate per 100 000 population due to migraine and 
tension-type headache by age, 2016
Shaded areas show 95% uncertainty intervals. Values are plotted at the midpoint of 5-year age categories.
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However, ageing has a lesser effect on headaches as 
these, and in particular migraine, are most common 
among young and middle-aged adults, and become less 
prevalent with old age.
The principal reason migraine has climbed from the 
seventh largest cause of YLDs in GBD 2015 to second 
place in GBD 201620,23 is that medication overuse 
headache used to be treated as a separate disease entity, 
but in GBD 2016 it was considered a sequela of either 
migraine or tension-type headache, with more than 
70% of medication overuse headache burden being 
reattributed to migraine. We believe this change in the 
status of medication overuse headache is correct, from 
both clinical and patho physio logical viewpoints, 
because medication overuse headache virtually never 
develops de novo, but almost always from either 
migraine or tension-type headache, and the presence of 
a primary headache is considered to be a prerequisite 
for medication overuse headache.10,24
A short supply of data is still a limitation in headache 
burden estimates. Although several epidemiological 
studies on headache have been done in the past decade 
in large and populous regions of the world where none 
existed before (ie, Russia, China, India, and parts of 
Africa), the majority of studies are still from high-
income countries, and there remain five regions of low-
income and middle-income countries without data for 
migraine. No data exist for populous countries like 
Indonesia, Vietnam, Bangladesh, Egypt, South Africa, 
and the Democratic Republic of Congo. In sub-Saharan 
Africa, only five countries have data on headache. For 
tension-type headache and medication overuse 
headache, the data are even scarcer. In addition, too few 
population-based studies give good estimates of average 
headache duration and frequency, which are necessary 
for calculation of time spent in the symptomatic state. 
The small number of studies did not allow us to 
differentiate the estimates of time spent with symptoms 
by location, although, in countries with better access to 
health care, the frequency and duration of migraine 
attacks would be expected to decrease with treatment. 
There is also a need to update results in many places, to 
get more reliable results (many old studies are of low 
quality) and possibly also to monitor secular trends in 
headache epidemiology. Because data on headache are 
poorly captured in national health surveys, and 
administrative data collections such as those from 
claims or primary care are unreliable measures of 
prevalence (appendix), it is desirable that surveys on 
headache be done in many more places, and preferably 
at regular intervals as part of national health reporting 
systems.
In GBD, DisMod-MR 2.1 makes it possible to adjust 
results of studies that were done using suboptimal case 
definitions or methods. However, an important aspect 
that has not yet been taken into account in the model is 
the distinction between definite and probable diagnoses 
of migraine and tension-type head ache. People with a 
definite diagnosis fulfil all ICHD diagnostic criteria for 
the disorder, whereas those with probable diagnoses do 
not meet one of them; the probable diagnosis is not 
meant to signify a separate nosological entity. In a 
clinical setting, probable diagnoses are useful for 
patients for whom there is diagnostic uncertainty, but 
confirmation (or refutation) of the diagnosis is expected 
later. However, this will not be the case in epidemio-
logical studies and, unless the large number of probable 
cases are included for either migraine or tension-type 
headache as appropriate, these people will not be 
counted, despite experiencing headache-related 
disability. Several studies have investigated, in more 
detail, participants in epi demiological studies who 
received probable diagnoses. In the great majority, a 
definite diagnosis of migraine was withheld because 
attacks reportedly lasted less than 4 h (the minimum 






















































































Figure 5: Age-standardised disability-adjusted-life-years (DALY) rates for (A) migraine and (B) tension-type 
headache by 21 Global Burden of Disease regions by Socio-demographic Index (SDI), 1990–2016
The solid black line represents expected values based on SDI from a regression of all location data over the entire 
1990 to 2016 estimation period.
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resembled migraine closely, and was associated with 
considerable disability. Until 2000, the majority of 
studies reported only definite migraine, and not both 
definite and probable diagnoses. After 2000, more 
studies reported both types, and these studies indicate 
that the prevalence of probable migraine is almost as 
high as that of definite migraine.26,28 Future iterations of 
GBD should therefore find a reasonable and consistent 
way to deal with probable migraine because it is a 
common cause of disability that otherwise will be 
unaccounted for. Similar arguments can be made for 
probable tension-type headache, although knowledge of 
this headache type is far less, and the YLDs missed by 
omitting this are fewer because of the much lower 
disability weight of tension-type headache compared 
with migraine.
Another problem is the handling of chronic headache 
disorders (ie, present on 15 or more days per month 
for more than 3 months). Many of these headaches will 
fall into the categories of chronic migraine, chronic 
tension-type headache, or medication overuse head-
ache, but the high frequency of headaches tends to blur 
the features necessary for diagnosis. These headaches 
become even more difficult to diagnose with certainty 
in cross-sectional epidemiological studies based on 
questionnaires, especially when these are self-admin-
istered or applied by lay interviewers. With the 
exception of medication overuse headache, which is 
diagnosed by enquiry into medication use, these head-
aches are usually lumped into a descriptive category of 
headache on 15 or more days per month, and not 
counted in GBD. Hence, there might be additional, and 
perhaps considerable, headache-related morbidity that 
is not captured by the diagnoses used in GBD.
Despite efforts to adjust for methodological diff-
erences between studies, part of the variation between 
countries might be due to residual measure ment error, 
rather than true variation. Efforts have been made to 
standardise the methods for studies on prevalence and 
burden of headache,11 and in the future adherence to 
these will hopefully make it easier to compare the 
burden over geographical borders and time periods. 
One of the greater challenges in modelling headache is 
the poor knowledge of predictors. Such predictors help 
to stabilise disease models in the sense that they adjust 
data points that are affected by measurement error.
Another problem concerns how to estimate the 
proportion of time during which people with a headache 
disorder actually have headache (time in symptomatic 
state). This difficulty exists partly because average 
duration and frequency of headaches are usually 
reported in categories, and estimates thus depend on 
choice of mean value in each category, and partly 
because the present figures rely on older studies that 
are of rather poor general quality. Better estimates can 
probably be obtained with a more systematic analysis of 
individual record data in some of the major surveys 
done in the past 10 years that are of higher quality than 
earlier studies.
Despite these methodological challenges, headache 
disorders are ubiquitous and contribute to a large 
burden of lost health. Sizeable resources would be 
needed to prevent or alleviate this burden in the 
hundreds of millions of people with headache world-
wide. Until now, most interventions have aimed at the 
management of symptoms, but preferable for such an 
immense public health problem might be modification 
at a population level of risk factors, if such can be 
identified. This intervention would require greater 
knowledge of the modifiable factors that drive headache: 
several have been suggested with varying degrees of 
scientific support, such as obesity, smoking, indoor and 
outdoor air pollution, level of physical activity, altitude, 
blood pressure, and level of stress.29–32 Of these factors, 
altitude and stress are not included as risks in GBD. 
For the other postulated risks, the evidence for an effect 
on headaches is, in our opinion, insufficient. Potential 
headache risk factors should be tested against GBD 
causal criteria for inclusion of risks and associated 
outcomes.33 If none of these risk factors pass the 
criteria, more and better epidemiological and patho-
physio logical studies should be done to prove or refute 
hypotheses about causation.
Headache disorders do not appear to be strongly 
linked to socioeconomic development, as measured by 
SDI (table). The previous notion that headache was 
mainly a disorder of high-income countries and 
particularly prevalent among the wealthy, is refuted by 
the present study, but neither is the opposite true. 
Hence, no significant reduction in the global burden of 
headache can be expected from the demographic and 
epidemiological transitions22 that large parts of the 
world are presently undergoing, because no clear 
pattern of decreasing YLD rate with increasing SDI 
exists. It can, however, be predicted that the relative 
importance of headaches will further increase as the 
importance of other disorders, such as malnutrition, 
infections, maternal and child diseases, and cardio-
vascular and other fatal non-communicable disorders 
decreases. Although a socioeconomic index like the 
SDI does not reflect differences in headache prevalence 
when applied across countries and cultures, the 
possibility that such factors are important within a 
country or region cannot be eliminated. A socio econ-
omic gradient, to the effect that low socioeconomic 
status is linked to higher headache prevalence, has 
been shown in countries of high, middle, and low 
income.15,34–36
Even if it proves difficult to establish, with reasonable 
certainty, that modifiable risk factors exist for headache, 
the results of GBD definitely give a strong call for 
improving health care for headache. This call involves 
the inclusion of headache care in existing health-care 
systems, and not only in the high-income part of the 
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world. Implementation of a headache service in 
Georgia, a country where none existed previously, has 
been economically sustainable.37 An educational 
programme among general practitioners in Estonia has 
been shown to reduce unnecessary referrals to 
specialists and special examinations.38 A programme to 
increase competence in headache care in China is now 
being implemented.39 Some simple remedies and 
methods, like aspirin for attack treatment and ami-
triptyline for prevention of migraine, together with 
provision of information for patients and education for 
health-care providers, should be highly cost-effective in 
low-income and middle-income countries.40 A study 
from European and Latin American countries has 
shown that discontinuation of medication overuse can 
reduce the proportion of severely disabled patients with 
medication overuse headache by almost 60%.41 This 
study also indicates that increased awareness of the 
danger of non-critical use of acute medication might 
prevent millions of people from developing this 
prevalent and disabling disorder.
In high-income parts of the world, the results 
presented here also highlight a strong moral obligation 
to allocate more resources to research aimed at 
understanding the mechanisms of headache to enable 
development of more effective prevention and 
treatments. At the same time, current treatments need 
to be recognised as ineffective more because of poor 
availability than inefficacy, and health services must do 
a better job of reaching people if new treatments are to 
have an effect.42 For the pharmaceutical industry, the 
market for proven cost-effective remedies is huge, as is 
the potential for a large decrease in pain and disability, 
and an increase in productivity, for the global 
community.
In conclusion, major limitations still exist in the GBD 
headache burden estimations, the most notable being 
the short supply of epidemiological data from large 
parts of the world, the paucity of studies giving data on 
average time with headache, and great methodological 
heterogeneity. Nevertheless, GBD 2016 confirms that 
headache, and in particular, migraine, is a large public 
health problem in both sexes and all age groups 
worldwide, but most so in young and middle-aged 
women. Headache is not limited to the high-income 
part of the world and, unless action is taken, it is here to 
stay: there is no indication that the demographic and 
epidemiological transitions alone will improve the 
situation. Rather, these profound changes which reduce 
mortality will increase the relative importance of 
headache for public health.
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